Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
3.015 USD | -4.29% | -5.92% | -6.21% |
Mar. 08 | Ovid Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Mar. 08 | Earnings Flash (OVID) OVID THERAPEUTICS Reports Q4 Revenue $141,562 | MT |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-6.21% | 223M | C | ||
-1.95% | 104B | B+ | ||
+1.78% | 97.42B | B+ | ||
+0.79% | 22.2B | B | ||
-17.82% | 21.23B | B+ | ||
-11.11% | 18.33B | A- | ||
-42.83% | 16.35B | A- | ||
-17.15% | 15.06B | B | ||
+3.51% | 13.98B | C+ | ||
+33.42% | 11.66B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- OVID Stock
- Ratings Ovid Therapeutics Inc.